EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

Hedera Dx SA1,000 enrolled

Overview

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease. * Intention-to-initiate first-line tumour therapy for this advanced disease. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * At least 18 years of age on the day of signing informed consent, and capable of signing informed consent. Exclusion Criteria: * Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.

Locations (4)

Université de Lorraine

Nancy, Lorraine, France

RECRUITING

University of Naples "Federico II"

Naples, Italy

RECRUITING

General Universitario Gregorio Marañon

Madrid, Spain

NOT_YET_RECRUITING

Outcomes

Primary Outcomes

Actionable biomarkers

Proportion of patients with successful molecular profiling and detectable actionable biomarkers

Time frame: At baseline

Central Contacts

Dr. Christian Meisel, MD PhD

CONTACT

+41 21 588 16 54 HederaDxStudies@hederadx.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.